C71T
CANCELLED SECTION 71
10/07/2026
Voltar para busca
Dado oficial do USPTO
FINLEE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
02/04/2019
Data de registro
24/12/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/07/2026
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
TULLY, MATTHEW
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparationspharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematologypharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for use in tissue and organ transplantationpharmaceutical preparations and substances for preventing organ rejection; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmologypharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/04/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/04/2020
FIMP
FINAL DISPOSITION PROCESSED
06/04/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/03/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
24/12/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2019
PUBO
PUBLISHED FOR OPPOSITION
08/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
05/10/2019
RFNT
REFUSAL PROCESSED BY IB
20/09/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/09/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/09/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/09/2019
RFRR
REFUSAL PROCESSED BY MPU
04/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/08/2019
ALIE
ASSIGNED TO LIE
28/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/08/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/08/2019
CNRT
NON-FINAL ACTION WRITTEN
20/08/2019
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
15/08/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/08/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/08/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/07/2019
MAFR
APPLICATION FILING RECEIPT MAILED
23/07/2019
CNRT
NON-FINAL ACTION WRITTEN
22/07/2019
DOCK
ASSIGNED TO EXAMINER
17/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/07/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
15/07/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/07/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FINLEE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.